Pacira BioSciences (PCRX) vs Rapport Therapeutics (RAPP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Rapport Therapeutics (RAPP) over the past year, gaining 55.4% versus a gain of 10.3%. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.43 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCRX | RAPP |
|---|---|---|
| Share price | $36.39 | $29.85 |
| Market cap | $1.45B | $1.43B |
| 1-day change | +44.40% | -3.27% |
| YTD return | +40.61% | -1.62% |
| 1-year return | +55.45% | +10.31% |
| 5-year return | -31.60% | — |
| P/E ratio (TTM) | 103.97 | — |
| Forward P/E | 10.52 | — |
| EPS (TTM) | $0.35 | $-3.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.46 | $52.93 |
| 52-week low | $18.80 | $23.75 |
| Distance from 52-week high | -0.19% | -43.60% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -17.26% | +111.19% |
| Average volume | 1.03M | 359.60K |
| Shares outstanding | 39.86M | 47.98M |
| Employees | 825 | 84 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCRX has outperformed RAPP by 45.1 percentage points over the past year.
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
About Rapport Therapeutics
RAPP stock →Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
PCRX vs RAPP FAQ
Which is bigger, Pacira BioSciences or Rapport Therapeutics?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.43B for Rapport Therapeutics (RAPP).
Which stock has performed better over the past year, PCRX or RAPP?
PCRX returned +55.45% over the past 12 months, compared with +10.31% for RAPP (price return, excluding dividends). Past performance does not predict future results.
Are Pacira BioSciences and Rapport Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.